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During antiviral defense, interferon (IFN) signaling
triggers nuclear transport of tyrosine-phosphory-
lated STAT1 (PY-STAT1), which occurs via a subset
of karyopherin alpha (KPNA) nuclear transporters.
Many viruses, including Ebola virus, actively antago-
nize STAT1 signaling to counteract the antiviral
effects of IFN. Ebola virus VP24 protein (eVP24) binds
KPNA to inhibit PY-STAT1 nuclear transport and
render cells refractory to IFNs. We describe the
structure of human KPNA5 C terminus in complex
with eVP24. In the complex, eVP24 recognizes a
unique nonclassical nuclear localization signal
(NLS) binding site on KPNA5 that is necessary for
efficient PY-STAT1 nuclear transport. eVP24 binds
KPNA5 with very high affinity to effectively compete
with and inhibit PY-STAT1 nuclear transport. In
contrast, eVP24 binding does not affect the transport
of classical NLS cargo. Thus, eVP24 counters cell-
intrinsic innate immunity by selectively targeting
PY-STAT1 nuclear import while leaving the transport
of other cargo that may be required for viral replica-
tion unaffected.
INTRODUCTION
Interferons (IFNs) generate innate and adaptive immune re-
sponses to viral infections through a signaling cascade that re-
quires the activation of signal transducer and activator of
transcription (STAT) family transcription factors (Goodbourn
et al., 2000). Type I IFNs activate STAT1 and STAT2 through
phosphorylation by the Janus kinase (JAK) family members,
and type II IFN only activates STAT1 (Reich and Liu, 2006). Phos-
phorylation of tyrosine 701 on STAT1 (PY-STAT1) results in a
conformation that is recognized by a subset of the karyopherin
alpha (KPNA) family of nuclear transport factors (Chen et al.,Cell Hos1998; McBride et al., 2002; Meyer et al., 2002). Nuclear transport
of PY-STAT1 and binding to IFN-stimulated response elements
(ISRE) or interferon-gamma-activated site (GAS) elements
induce expression of IFN-stimulated genes (ISG) that confer an
antiviral state.
All KPNAs contain ten armadillo (ARM) repeats and are divided
into subfamilies based on sequences that dictate cargo speci-
ficity (Conti and Kuriyan, 2000; Conti et al., 1998). Cargo that
contain a classical nuclear localization signal (cNLS), which con-
sists of mostly basic amino acids, bind KPNA near ARMs 2–4
(major site) and 6–8 (minor site) (Chook and Blobel, 2001; Conti
and Izaurralde, 2001; Cook et al., 2007). In contrast, the NPI-1
subfamily (KPNA1, KPNA5, and KPNA6; also known as importin
a5, importin a6, and importin a7, respectively) mediates PY-
STAT1 nuclear transport, which depends on a nonclassical
NLS (ncNLS) (Sekimoto et al., 1997). Use of a distinct nuclear
transporter binding site presumably allows PY-STAT1 to translo-
cate to the nucleus without impacting regular nucleocytoplasmic
trafficking processes. Viruses target IFN signaling by inhibiting
distinct steps in the STAT1 activation and nuclear translocation
process, but these mechanisms vary, and many are poorly
defined (Yarbrough et al., 2014).
A hallmark of infection by filoviruses (Ebola virus [EBOV] and
Marburg virus [MARV]) is the rapid and potent suppression of
innate antiviral immune responses, which facilitates uncontrolled
viral replication and cytokine storm (Bray and Murphy, 2007;
Geisbert et al., 2003). As a result, high case fatality rates of up
to 90% are observed during outbreaks (Feldmann and Geisbert,
2011). EBOV mediates immune suppression through at least
three virally encoded proteins: surface glycoprotein (GP), virus
protein 35 (eVP35), and virus protein 24 (eVP24) (Basler and
Amarasinghe, 2009; Kaletsky et al., 2009; Leung et al., 2010;
Zhang et al., 2012a). Among these, eVP24 acts in a cell-intrinsic
manner to inhibit IFN signaling and render cells refractory to
exogenous IFN treatment by targeting the NPI-1 subfamily of
KPNAs, but the molecular mechanism of this process is
unknown.
Cargo containing ncNLS sequences are often difficult to iden-
tify because ncNLS sequences lack consensus motifs. As a
result, the exact ncNLS binding site for PY-STAT1 as well as viralt & Microbe 16, 187–200, August 13, 2014 ª2014 Elsevier Inc. 187
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Figure 1. eVP24 Binds an ncNLS Site on KPNA5 Near C-Terminal ARMs 8, 9, and 10 with High Affinity and Specificity
(A) Coimmunoprecipitation experiments with FLAG antibody were performed from lysates of 293T cells cotransfected with plasmids for Flag-KPNA5 of various
lengths, as indicated in the figure and HA-eVP24. Western blots were performed for FLAG, hemagglutinin (HA), and b-tubulin. WCL, whole-cell lysate.
(legend continued on next page)
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Table 1. Data Collection, Structure Solution Statistics, and
Validation Results
Data Collection
Space group P3121
Unit Cell Parameters
a, b, c (A˚) 103.93, 103.93, 333.63
a, b, g () 90, 90, 120
Resolution range (A˚) 50–3.15 (3.20–3.15)*
Unique reflections 35,719 (1735)
Redundancy 6.0 (6.0)
Completeness (%) 96.2 (98.1)
Rmerge (%) 9.1 (95.3)
<I> / <s (I)> 14.8 (1.1)
CC1/2 (0.546)
Structure Solution and Refinement
Resolution (A˚) 35.12–3.15 (3.23–3.15)
Number of reflections 29,294
Completeness (%) 83.2 (37.2)
Nonhydrogen atoms 9,199
Rwork/Rfree (%) 21.6/24.9 (27.5/29.7)
Rmsd
Bond lengths (A˚) 0.004
Bond angles () 0.824
B Factors (A˚2)
Protein (chain A) 29.28
Protein (chain B) 29.42
Protein (chain C) 42.88
Protein (chain D) 53.52
Protein (chain E) 33.08
Protein (chain F) 52.91
Water 28.92
Ramachandran plot outliers (%) 0.26
MolProbity score 1.18
MolProbity clashscore 1.73
Summary of data collection and structure solution statistics for the eVP24
and KPNA5C complex and validation results from the MolProbity server.
*Values in parentheses are for the highest-resolution shell.
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VP24-Karyopherin a Complex Inhibits STAT Signalingantagonists that bind nuclear transporters has not been charac-
terized. In order to address this limitation, we characterized the
binding between eVP24 and the NPI-1 subfamily of karyopherins
by truncation/mutational analysis and defined the minimal struc-
tured region of eVP24 and C terminus of KPNA5 (KPNA5C).
Using theseminimal protein constructs, we determined the crys-(B) Raw ITC data and corresponding binding isotherms for MBP-tagged eVP24
sentative data are shown from at least two independent experiments. Control ex
(C) Asymmetric unit of eVP24/KPNA5C complex contains three complexes with 1
KPNA5C is shown in orange (mol F) and light gray (mol D and E). Only eVP24 resi
structure.
(D) Representative 1:1 complex structure between eVP24/KPNA5C reveals mult
(E) Alignment of a KPNA structure (yellow; PDB ID: 1BK5) with the C-terminal AR
(F) The three-helix construction of the ARM repeats and the ten ARM repeats of KP
and S5.
Cell Hostal structure of the eVP24 and KPNA5C complex. With the struc-
ture as a guide, we characterized eVP24 and PY-STAT1 binding
to the nuclear transporter as well as the mechanism of innate
immune antagonism by eVP24. The data reveal direct competi-
tion between eVP24 and PY-STAT1 for the NPI-1 subfamily of
nuclear transporters, which promotes inhibition of cell-intrinsic
innate immune response and renders Ebola virus-infected cells
insensitive to IFN treatment.
RESULTS
KPNA5 C Terminus Is Necessary and Sufficient for
eVP24 Binding
In order to gain mechanistic insight into how eVP24 promotes
immune suppression, we characterized the eVP24/KPNA5 inter-
action. We used a series of Flag-KPNA5 truncation mutants from
which we identified residues 308–509 (KPNA5C) encompassing
ARMs 7–10 as theminimal region necessary for binding to eVP24
(1–251) (Figure 1A). Next, we carried out quantitative isothermal
titration calorimetry (ITC) studies, which revealed that KPNA5C
and DIBB-KPNA5 (66–509; lacking the importin b binding region
and the extreme C terminus) each bound eVP24 with similar high
affinities (Figure 1B), suggesting that key binding determinants
are located in KPNA5C. Using the minimal constructs, we deter-
mined the crystal structure of the KPNA5C and eVP24 complex
to a 3.1 A˚ resolution in order to further define the molecular basis
of the interaction interface. There are three copies of the com-
plex in the asymmetric unit, each consisting of KPNA5C and
eVP24 (Figures 1C–1D and Table 1). Structural comparison of
eVP24 protein in the complex to the free form suggests limited
structural change upon complex formation, as we observe only
0.83 A˚ backbone root-mean-square deviation (rmsd) between
these two structures (Figure S1, available online). In comparison
to previous KPNA structures, the KPNA5 ARMs 7–10 in the
eVP24/KPNA5C complex also show only minor conformational
changes upon eVP24 binding, and correspondingly the back-
bone rmsd for ARMS 7–10 is 0.98 A˚ (Figure 1E). Collectively,
these results demonstrate that ARMs 7–10 are sufficient to
bind eVP24; however, as discussed below, the minimal binding
region for eVP24 on KPNA5 is likely contained within ARMs
8–10 based on analysis of the complex.
The eVP24/KPNA5C Complex Reveals a Unique ncNLS
Binding Site
In the eVP24/KPNA5C structure, the interface between the two
molecules buried about 2,100 A˚2 of solvent accessible surface
area (Figure S2). In addition to burying a large solvent accessible
surface area, this interface displays high shape complementarity
judging from the shape complementary value Sc = 0.82 (for(residues 11–237) binding to KPNA5 66–509 (left) and KPNA5C (right). Repre-
periments show that MBP does not bind KPNA5 or KPNA5C.
:1 stoichiometry. eVP24 is shown in blue (mol C) and dark gray (mol A and B);
dues 16–231 and KPNA5C residues 332–506 were modeled in the final refined
iple structural interaction elements between the two molecules.
M repeats from the eVP24/KPNA5C complex structure.
NA proteins are shown. cNLS and ncNLS sites aremarked. See also Figures S1
t & Microbe 16, 187–200, August 13, 2014 ª2014 Elsevier Inc. 189
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ysis of residues in the interface reveals that the interface is largely
hydrophobic. Moreover, only limited charge complementarity is
observed (Figure S2B). eVP24 interacts with KPNA5 ARMs 8, 9,
and 10 (Figures 1E and 1F), which is a unique ncNLS binding site
for KPNA transporters (Cook et al., 2007; Yarbrough et al., 2014).
In the structure of the complex, there are three clusters of eVP24
residues that contact KPNA5C (Figures 2, S1, and S3A). Amajor-
ity of cluster 1 contacts are derived from helix 6 to helix 7,
including the linker between helices 6 and 7. Contact residues
include L115, L121, W125, T128, T129, N130, T131, N135,
R137, T138, and R140 (Figure 2). In addition, there are interac-
tions with KPNA5 ARMs 8–9 and 9–10 by eVP24 residues
Q184, N185, and H186 (cluster 2) and D124, T128, and T129,
respectively (Figure 2). The third cluster (cluster 3) of residues
is between 201 and 207, including L201, E203, P204, D205,
and S207, which show hydrogen bonds and nonbonded con-
tacts with KPNA5. eVP24 helix 6 and the helix 2 from ARMs 9
and 10 of KPNA5C form a hydrophobic core, which appears to
provide high shape complementarity and buries a large surface
area at the interface. Amino acids 142–146 were defined previ-
ously as being important for KPNA5 binding (Mateo et al.,
2010). Although these are not located in the binding interface,
the proximity of residues 142–146 to contact residues suggests
that their mutation may influence the conformation of contact
residues (Mateo et al., 2010). Overall, the structure reveals that
eVP24 contributes a large number of residues to the binding
interface and that the sites of interaction on KPNA5 appear to
be distinct from previously described binding sites for other
KPNA interactors, including ncNLS-containing cargo (Cook
et al., 2007; Yarbrough et al., 2014).
KPNA5 ARM10 Is Required for eVP24 Binding
eVP24 selectively targets PY-STAT1 binding to the NPI-1 sub-
family of KPNAs and fails to interact with non-NPI-1 subfamily
KPNAs 2, 3, and 4, which also do not recognize PY-STAT1
(Reid et al., 2007). The structure indicates that fewer KPNA5 res-
idues than eVP24 residues contribute to the binding interface (23
for eVP24 versus 15 for KPNA5) (Figure 2). In all, we observe 15
conserved residues, of which 10 are identical in the NPI-1 sub-
family (Figure S3B). Of these KPNA5 residues, some located in
ARM10 helix 1 and helix 2, including E474, E475, D480, K481,
and E483, contact eVP24 (Figure 2C) but are not required for
eVP24 interactions, as mutation of these residues only shows
slightly diminished binding (Figure 3). In contrast, interface resi-
dues R396, R398, D431, V435, M436, Y477, F484, and S487 are
conserved only in the NPI-1 subfamily of KPNA1, KPNA5, and
KPNA6, but not in the non-NPI-1 subfamily KPNA2, KPNA3,
and KPNA4. These NPI-1-specific interface residues in the
eVP24/KPNA5 complex may explain how eVP24 achieves spec-
ificity for the NPI-1 subfamily of KPNAs despite high sequence
and structural similarities among KPNA proteins. Among the
three clusters that contact KPNA5, clusters 1 and 3 are con-
served among different EBOV but vary between eVP24 and
MARV VP24 (mVP24), which, despite homology to eVP24,
does not block IFN signaling (Figure S3A) (Valmas et al., 2010).
This suggests that these two clusters may serve as the speci-
ficity determinants of eVP24. In addition to these sequence-
based assessments, further structural analysis of eVP24 and190 Cell Host & Microbe 16, 187–200, August 13, 2014 ª2014 ElsevimVP24 also supports the importance of residues from clusters
1 and 3 as important contributors to KPNA binding.
In the structure, KPNA5 ARM10 helix 3 appears to stabilize the
structural features recognized by eVP24. Although ARM10 helix
3 does not contact eVP24 in the structure, it is still important for
interaction, as deletion of helix 3 results in loss of binding (Fig-
ure 1A; 1–490 KPNA5). In the absence of evidence for direct con-
tact, we can attribute a structural role for helix 3, where helix 3
may stabilize ARM10 helices 1 and 2, the two helices in
ARM10 that contact eVP24. To address this possibility, we as-
sessed the helical stability of ARM10 using atomistic simula-
tions. The results show that helices 1 and 2 are highly unstable
in isolation. However, the helicities of these segments increase
significantly when they are in the context of ARMs 7–9 and helix
3 from ARM 10 (Figure 2D). These results demonstrate that
KPNA5 ARM10 is a major binding determinant that also contrib-
utes to the binding specificity of eVP24.
eVP24 Makes Extensive Multiresidue Contacts at the
Interface
We evaluated the contributions of individual amino acids of
eVP24 to the KPNA5 binding interface by coimmunoprecipitation
(coIP). A list of mutations used in the study is shown in Figures 3A
and 3B. With the exception of R137A, all single eVP24 point
mutants tested showed only minor (<20%) loss of KPNA5
binding (Figure 3C). In contrast, several multiresidue mutants
exhibited near-complete loss of KPNA5 binding, including
F134A/M136A (cluster 1A mut), R137A/T138A/Q139A (cluster
1C mut), Q184A/N185A/H186A/R137A/T138A (cluster 2 mut +
R137A/T138A), and L201A/E203A/P204A/D205A/S207A (cluster
3 mut), although the latter two mutants were expressed to lower
levels compared to other eVP24s (Figures 3C, 3D, and S3). All
residues selected in these multiple mutants, with the exception
of cluster 1A mut, were direct contact residues that were
observed within 5 A˚ of KPNA5C in the structure. These results
suggest that the high-affinity interaction surface on eVP24 spans
several loop regions and, with the exception of R137A, multiple
mutations are necessary to obtain near-complete loss of binding.
Residues Specific to NPI-1 Subfamily of KPNAs Make
Critical Interface Contacts
There are 12 residues of KPNA5 that form nonbonded contacts
with eVP24 in the structure of the eVP24/KPNA complex. From
these, we selected a representative subset of residues that
included residues conserved among the six human KPNAs
(E474, D480, and E483) and a few residues that are identical
only in the NPI-1 subfamily of KPNAs (R398, D431, Y477,
F484, and S487) (Figure S3B). Most KPNA5 single-residue mu-
tants minimally impacted the interaction with eVP24 (Figure 3E).
However, the following four mutants are the notable exceptions:
R398A, Y477A, Y477G, and F484A (Figures 3E and 3F). Y477
was implicated previously as an important residue for PY-
STAT1 binding with quantitative binding studies showing >20-
fold lower binding affinity to KPNA1 (Nardozzi et al., 2010). In
the structure of the complex, Y477 of KPNA5C makes extensive
nonbonded contacts with eVP24. The binding of eVP24 to Y477A
and Y477G shows partial loss of binding in coIP experiments,
and the level of attenuation appears to correspond to the hydro-
phobicity of the side chain (Figure 3G). We also mutated severaler Inc.
AC
D
B Figure 2. The eVP24 and KPNA5 Interface Reveals Exten-
sive Interactions
(A–C) Extensive hydrogen bonding and hydrophobic interactions
are observed between eVP24 and KPNA5 ARM 8 (A), ARM 9 (B),
and ARM 10 (C). LigPlot+ diagrams (top) showing protein-protein
interactions between eVP24 and KPNA5. Protein side chains are
shown as ball and sticks. Hydrogen bonds are shown as green
dotted lines. Spoked arcs represent nonbonded contacts. PyMOL
representation of the highlighted protein-protein interactions is
shown on the bottom. A total of 2,100 A˚2 is covered between the
two molecules.
(D) Intrinsic and context-dependent a-helical propensities of
KPNA5 ARMhelices H1, H2, and H3. The ordinate shows the value
of fa (0% fa% 1) at 298 K. The error bars refer to the SEM.
See also Figure S2.
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Figure 3. Multiple Residues from KPNA5 ARMs 8–10 Are Necessary and Sufficient for eVP24 Binding
(A) Summary of eVP24 mutants, which were grouped based on the three main residue clusters.
(B) Summary of KPNA5 mutants used in the study, grouped based on their location on the ARM repeats 8–10.
(C andD) CoIP experiments, precipitating with anti-HA antibody, were performed on lysates from 293T cells cotransfectedwith plasmids for Flag-KPNA5 andHA-
eVP24 single-residue (C) or multiple-residue (D) eVP24 mutants as indicated.
(E–G) CoIPs with Flag antibody were carried out on lysates cotransfected with HA-eVP24 WT and Flag-KPNA5 (E) single-residue KPNA5 mutants, (F) at residue
Y477 in the ARM10 hinge, or (G) multiple-residue KPNA5mutants as indicated.Western blots were performed for Flag, HA, and b-tubulin.WCL, whole-cell lysate;
E, pCAGGS empty vector control.
See also Figures S3 and S4.
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VP24-Karyopherin a Complex Inhibits STAT Signalinggroups of residues within KPNA5. R396A/R398A (ARM 8 mut),
D431A/T434A/M436A (ARM 9 mut), and Y477G/D480A/F484A/
S487A (ARM 10 mut) all showed near-complete loss of binding
(Figures S3A and 3G). In vitro pull-down assays between
KPNA5C and eVP24 confirmed that ARMs 8–10 are necessary
for binding using E. coli-expressed proteins. These studies
also confirmed that the eVP24 residues critical for full-length192 Cell Host & Microbe 16, 187–200, August 13, 2014 ª2014 ElseviKPNA5 binding are also important for binding to the truncated
KPNA5C protein (Figure S4), further supporting the notion that
the minimal eVP24 binding domain in KPNA5 resides within res-
idues in ARMs 8–10. Collectively, these data are also consistent
with the observed combined buried surface area of >2,000 A˚2
and support the hypothesis that eVP24 and KPNA5 share a
unique binding interface.er Inc.
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Figure 4. eVP24 and PY-STAT1 Share an Overlapping Binding Site on KPNA5
(A–D) 293T cells were treated with human IFNb (1000 U/ml) for 30 min. CoIPs with HA or Flag antibody were performed as indicated on the 293T cell lysates
transfected with (A) HA-tagged eVP24 or Nipah virus V protein (NipV), (B) KPNA5 truncation mutants, (C) KPNA5 single- and multiple-residue mutants from the
eVP24/KPNA5C structural interface, and (D) KPNA5 Y477 single mutants. Western blots were performed for PY-STAT1, STAT1, and Flag or HA. WCL, whole-cell
lysate; E, pCAGGS empty plasmid transfection. See also Figure S1.
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To clarify the extent to which the large interface occupied by
eVP24 on KPNA overlaps with the PY-STAT1 binding site,
mutant KPNA5 proteins were tested for eVP24 and PY-STAT1
binding. Coprecipitation experiments show that eVP24 does
not detectably interact with STAT1 in either its unphosphorylated
or tyrosine-phosphorylated form, whereas Nipah virus V (NiV)
protein, a known STAT1 binder, readily interacted with STAT1-
GFP and PY-STAT1-GFP (Figure 4A) (Ciancanelli et al., 2009;
Reid et al., 2006). Analogous experiments examining interaction
with endogenous STAT1 also detected NiV V-STAT1 interaction
but did not detect eVP24-STAT1 interaction (data not shown).
These results suggest that direct binding to STAT1 is unlikely
to explain the inhibitory effects of eVP24 on STAT1 signaling.
The C terminus of KPNA5, including the eVP24 binding site of
ARMs 8–10, was required for PY-STAT1 interaction (Figure 4B).
The extreme C-terminal region of KPNA5 (residues 510–539)
also appears to be important for PY-STAT1 binding, as the trun-
cationmutants of KPNA lacking residues 510–539 show reduced
PY-STAT1 binding. These observations are consistent with pre-
vious observations suggesting an extensive binding interfaceCell Hosbetween PY-STAT1 and KPNA (Nardozzi et al., 2010; Reid
et al., 2007). However, these previous studies did not definitively
identify the specific ncNLS binding site on KPNA or the ncNLS of
PY-STAT1. Additionally, several single-residue mutants (T434A,
E474A, Y477A, Y477G, and F484A) in KPNA5 attenuated or
abolished binding to PY-STAT1 (Figures 4C and 4D). For
example, the Y477G mutation in KPNA5 leads to near-complete
loss of binding (Figure 4D). In non-NPI-1 subfamily KPNA pro-
teins, the residue corresponding to Y477 in the structure is
glycine, suggesting that this residue may play an important role
in determining binding specificity. These results support a model
where the KPNA5-eVP24 binding interface on KPNA5 overlaps,
at least partially, with the ncNLS binding site for PY-STAT1,
setting up a direct competition between eVP24 and PY-STAT1
for the NPI-1 subfamily KPNA binding during viral infections.
eVP24 Binding Interface Mutants Show Diminished
Inhibition of PY-STAT1 Nuclear Transport
Next, we assessed the functional impact of eVP24 binding to
KPNA5C on STAT1-mediated nuclear transport and signaling.
Addition of IFNb to empty vector-transfected cells triggeredt & Microbe 16, 187–200, August 13, 2014 ª2014 Elsevier Inc. 193
AC
D
B Figure 5. Recognition of a Shared ncNLS
Binding Site on KPNA by eVP24 Is Important
for Inhibiting PY-STAT1 Nuclear Localiza-
tion and ISG Induction
(A and B) eVP24/KPNA5 interface mutants R137A
and cluster 3 mut fail to inhibit IFN-mediated
STAT1 nuclear translocation. (A) Vero cells were
untreated or mock treated with IFNb for 30 min to
induce STAT1 nuclear localization (empty plasmid
[E] + IFNb). (B) Ectopic expression of eVP24 WT or
mutants differentially affects PY-STAT1 trans-
location to the nucleus after IFNb treatment.
White arrows highlight IFNb-treated cells that also
express eVP24 WT or eVP24 mutants. Represen-
tative data from one of two independent experi-
ments is shown.
(C) The ability of eVP24 to inhibit induction of the
ISG54 promoter was assessed. 293T cells were
cotransfected with an ISG54 firefly luciferase re-
porter, a constitutively expressedRenilla luciferase
plasmid, and the indicated eVP24 expression
plasmids. The values represent themean and SEM
of six samples, and statistical significance was
assessed by a one-way ANOVA comparing indi-
vidual mutants to the corresponding eVP24 WT
transfection, where ***p < 0.001, **p < 0.01, and
*p < 0.05. E, pCAGGS empty plasmid transfection.
(D) eVP24 competes with PY-STAT1 for binding to
KPNA5. FLAG-KPNA5wasused tocoIPPY-STAT1
in the presence or absence of eVP24 or mutants
with attenuated KPNA5 binding. Two concentra-
tions (2 and 4 mg) of eVP24 plasmids were tested.
E, pCAGGS empty plasmid transfection.
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of eVP24 inhibited STAT1 relocalization. Using a similar assay,
we tested eVP24 mutants with reduced KPNA5 binding activity,
including R137A, K142A, cluster 1D mut, and cluster 3 mut mu-
tants, in order to assess their ability to inhibit PY-STAT1 nuclear
trafficking. Resulting data, shown in Figure 5B, reveal reduced in-
hibition of PY-STAT1 translocation in response to IFNb by eVP24194 Cell Host & Microbe 16, 187–200, August 13, 2014 ª2014 Elsevier Inc.mutants exhibiting impaired KPNA5 bind-
ing. Consistent with its lower impact on
eVP24-KPNA5 binding, the eVP24 K142A
mutant only partially inhibited PY-STAT1
nuclear accumulation, whereas mutants
that abolishbindingshowacorresponding
near-complete loss of inhibitory activity
against PY-STAT1 nuclear localization
(Figure5B).Collectively, these results sug-
gest that direct binding of eVP24 to NPI-1
subfamily of KPNAs likely explains the in-
hibition of PY-STAT1 nuclear import in
EBOV-infected cells that was previously
observed by Reid et al. (2006).
eVP24 WT, But Not Interface
Mutants, Can Successfully Block
ISRE Activity
STAT1 phosphorylation is required for
type I and II IFN responses. Specifically,the type I IFNs provide cell-intrinsic innate immunity through
the induction of ISRE genes that results in an antiviral state.
Therefore, we tested the ability of eVP24 wild-type (WT) or
eVP24 interface mutants to inhibit activation of the ISG54 pro-
moter using dual reporter assays. As expected, eVP24 WT in-
hibits ISRE induction, while cluster 1 and cluster 3 mutants
with impaired KNPA5 binding exhibited a corresponding loss
Cell Host & Microbe
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despite making several contacts with KPNA5, cluster 2 dis-
played WT levels of ISRE activity, suggesting that this region is
not important for function. Among individual mutants, R137A
andR140A appear to display the highest impact on ISRE activity.
Similarly, cluster 3mutants show the highest level of activity loss.
The correlation between the level of ISRE induction and the abil-
ity of eVP24 mutants to bind KPNA further support a model
where eVP24 binding to KPNA limits PY-STAT1 nuclear localiza-
tion, resulting in the inhibition of cell-intrinsic innate immune
signaling.
eVP24 Competes with PY-STAT1 for KPNA Binding
A combination of the eVP24/KPNA5C complex structure and the
biochemical analysis of the binding interface described above
suggest that the eVP24 binding site on KPNA5 partially overlaps
with the PY-STAT1 binding site. Ourmeasured affinity for KPNA5
with eVP24 is in the low nanomolar range (KD = 1–10 nM for
eVP24/KPNA5) (Figure 1B). In a similar experiment, we observe
that PY-STAT1bindsKPNA5with amicromolar dissociation con-
stant, which is about 1000-fold weaker (Figure S6A). In agree-
mentwith these studies,wewere unable to observemeasureable
binding activity between KPNA5 and unphosphorylated STAT1
(U-STAT1) (Figure S6A). A previous study reported that PY-
STAT1bound toKPNA1with aKD ranging from150–191nM (Nar-
dozzi et al., 2010), approximately 30-fold less than KPNA1/5
binding to eVP24. The observed differences are likely due to
changes in the experimental conditions or may reflect the spec-
ificities between KPNA1 and KPNA5 for binding to PY-STAT1.
Next, we tested the direct competition model by assessing the
ability of eVP24 WT to block KPNA5 interaction with PY-STAT1.
As shown in Figure 5D, eVP24 WT protein exhibited near-com-
plete inhibition of KPNA5 interaction with PY-STAT1. eVP24
R137A, which exhibits reduced but measurable KPNA5 binding,
displayed a slightly diminished dose-dependent inhibitory activ-
ity toward the interaction between PY-STAT1 and KPNA5. In
contrast, two eVP24 mutants, cluster 1D mut and cluster 3 mut,
which showed greatly reduced KPNA5 binding in coIP assays,
displayed a significantly diminished ability to block the interaction
at the concentrations tested (Figure 5D). These competition as-
says,whereeVP24 (or eVP24mutants) andPY-STAT1have equal
probability to interact with KPNA, further support a model where
inhibition of PY-STAT1 nuclear localization by eVP24 is due to
direct competition by eVP24 for NPI-1 subfamily KPNA binding.
eVP24 and cNLS Cargo Occupy Independent Binding
Sites on NPI-1 Subfamily KPNAs
Nucleocytoplasmic trafficking is important for normal cellular
processes and for responses to extracellular stimuli. Previous
studies have shown that PY-STAT1, produced in response to
type I IFNs, can bind KPNAs independent of cNLS cargo binding
(Melen et al., 2003; Sekimoto et al., 1997) (Figures 6A and 6B). To
test whether eVP24 and cNLS cargo occupy independent bind-
ing sites on KPNA5, we conducted two sets of experiments.
First, we tested the ability of cNLS cargo to associate with and
translocate into the nucleus through KPNA association. In order
to overcome potential redundancy of KPNAs for cNLS-contain-
ing cargo, we specifically tested the ability of eVP24 to affect
KPNA interaction with deleted in breast cancer 1 (DBC1) protein,Cell Hoswhich uses a validated basic cNLS to associate with KPNA1
and KPNA5 and mediate its nuclear import (Wa¨lde et al., 2012).
As shown in Figure 6C, Myc-tagged DBC1 can associate with
KPNA1 and KPNA5. The presence of increasing levels of
eVP24 does not appear to inhibit DBC1 association with
KPNA1 or KPNA5. Therefore, these results suggest that the
cNLS binding site for DBC1 and the eVP24 binding site, which
is a ncNLS binding site on NPI-1 subfamily KPNAs, are separate.
As a quantitative test of themodel, where cNLS and the ncNLS
binding site for PY-STAT1 and eVP24 on NPI-1 subfamily KPNA
is distinct, we conducted competition ITC experiments for
several cNLS peptide/KPNA combinations in the presence or
absence of eVP24. Specifically, we tested monopartite cNLS
(SV40 peptide) binding to KPNA1 or bipartite cNLS cargo (nucle-
oplasmin peptide) binding to KPNA1 and KPNA5 (Figures S6B–
S6E). Comparison of KPNA1 alone with KPNA1 in a 1:1 complex
with eVP24 reveals that for cNLSs, such as SV40, or for cargo,
such as DBC1, the binding sites for cNLS and ncNLS for PY-
STAT1/eVP24 are distinct (Figure S6C). Similarly, our data for
the bipartite cNLS also confirm that the eVP24 binding to
KPNA1 or KPNA5 does not significantly impact cNLS binding
(Figures S6D and S6E). However, we do observe a 2-fold differ-
ence for nucleoplasmin bipartite NLS peptide binding to KPNA1
and KPNA5 in the presence or absence of eVP24. This 2-fold dif-
ference is likely due to allosteric effects, as the eVP24 binding
site and the minor cNLS binding sites are located in KPNA5
ARM8. Taken together, these results support amodel for distinct
binding sites for cNLS and the PY-STAT1-specific ncNLS recog-
nized by eVP24 on KPNA5 (and other NPI-1 subfamilymembers).
Therefore, eVP24, like PY-STAT1, is unlikely to impact nuclear
transport of cNLS bearing cargo by KPNA.
eVP24 and the Related mVP24 Display Structural
Differences Near the KPNA Binding Residue Clusters
In contrast to eVP24, mVP24 lacks IFN antagonist activity (Val-
mas et al., 2010). Comparison of the mVP24 and eVP24 se-
quences suggest that there are major differences in the primary
sequence of the three eVP24 clusters, which contribute signifi-
cantly to KPNA5 binding (Figure S3A). In addition to the differ-
ences in their sequence, structural comparisons also reveal
significant differences near these clusters between eVP24 and
mVP24 (Figure S5), suggesting that the differences in the primary
sequence also contribute to structural differences. For example,
the region surrounding cluster 3 shows the most apparent struc-
tural change, where the mVP24 structure (Zhang et al., 2014)
shows an extended antiparallel b strand connected by a short
loop; the corresponding region in eVP24 consists of two short
antiparallel b strands connected by linkers and a short a helix
(Figure S5) (Edwards et al., 2014; Zhang et al., 2012b). Thus,
sequence and structural differences near key clusters of
eVP24 that are important for KPNA5 interaction likely explain
the differences in observed IFN-signaling antagonist properties
between EBOV and MARV VP24 proteins.
DISCUSSION
Innate immune responses to pathogens can dictate the out-
comes of infections. During outbreaks, EBOV infections result
in high case fatality rates in part due to virally encoded immunet & Microbe 16, 187–200, August 13, 2014 ª2014 Elsevier Inc. 195
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VP24-Karyopherin a Complex Inhibits STAT Signalingantagonists. In addition to virally encoded inhibitors of type I IFN
production, such as filoviral VP35 proteins, EBOV infections are
also refractory to type I and II IFN treatments. Type I and II IFNs
activate antiviral responses through JAK/STAT signaling. In the
JAK/STAT signaling pathway, a key committal step is the phos-
phorylation and nuclear translocation of STAT1, which can form
either homodimers with another molecule of PY-STAT1 or heter-
odimers with STAT2. In each of these pathways, PY-STAT1 and
nuclear translocation via NPI-1 subfamily KPNAs is important for
antiviral gene expression. The use of a unique ncNLS binding site
on these KPNAs by the host provides a mechanism for rapid
recruitment of PY-STAT1-associated transcription complexes
to the nucleus. It is likely that this ncNLS-mediated import of
PY-STAT1 is independent of normal nuclear transport, which is
typically coordinated through the direct recognition of a cNLS
by KPNAs. Through a combination of structural and biochemical
approaches, we define the molecular basis for eVP24-mediated
inhibition of cell-intrinsic immune responses and describe a key
molecular determinant that is important for PY-STAT1 transport
(summarized in Table S1 and Figure 6B). A previous study using
in vitro binding assays reported that U-STAT1 can also bind to
eVP24, suggesting an alternate mechanism by which eVP24
may limit nuclear STAT1 (Zhang et al., 2012b). Our cell-based
data (see Figure 4A) as well as previous studies by Reid et al.
(2006) and Pichlmair et al. (2012) do not support this model
proposed by Zhang et al. (2012b). Instead, our data support
a model where competitive and preferential binding of eVP24
to the specific nuclear transporters from the NPI-1 subfamily
of KPNAs instead of PY-STAT1 results in diminished ISRE
activation, which contributes to the observed eVP24-mediated
inhibition of cell-intrinsic innate immune signaling, including
the resistance of EBOV-infected cells for IFN treatment
(Figure 6D).
Although EBOVs and MARVs are closely related and share
identifiable genome organization, including similar open reading
frames with high sequence similarities, these two genera of
viruses also exhibit significant differences. A previous study by
Valmas et al. (2010) revealed that unlike eVP24, mVP24 does
not inhibit JAK/STAT signaling. Consistent with this observation,
our recent studies revealed that mVP24 can activate host antiox-
idant response element genes, which likely provides additional
support for viral growth (Edwards et al., 2014). Evaluation of
our results here reveals that the sequences near cluster 1 and
cluster 3 are different between these two VP24s. Given the
importance of these regions to KPNA binding by eVP24, it isFigure 6. Model of eVP24 Inhibition of KPNA-Mediated STAT1 Signalin
(A) Schematic diagram illustrating the domain organization of KPNA containing an
of which is comprised of 3 a helices (H1, H2, and H3), and a short C terminus. eVP2
green). Overlapping binding site between eVP24 and KPNA5 is shown as a solid b
are shown as a black dotted line.
(B) Relative locations of cNLS and ncNLS sites based on available data, includin
(C) CoIP experiments with Flag antibody were performed on lysates of 293T ce
concentrations of 2 and 4 mg of HA-eVP24 as indicated. Western blots were perfor
and Flag tags.
(D) Model of KPNA (PDB ID: 1BK5) in cylinder representation. The major and min
ARMs 6–8, respectively. The ncNLS used by PY-STAT1 or the KPNA binding site
STAT1 ± cNLS cargo can translocate into the nucleus. In contrast, eVP24 binding,
nuclear translocation, but not the transport of cNLS containing cargo.
See also Figures S6 and S7 and Table S1.
Cell Hoslikely that these regions, specifically those that make direct con-
tact with KPNAs, are important for discrimination. Interestingly,
clusters 1 and 3 are highly conserved among different EBOV
species. In contrast, cluster 2 residues show limited sequence
conservation. These sequence and structural variations between
eVP24 and mVP24, together with the structural results from this
study, provide a basis by which functional specificity of filoviral
VP24 proteins can be defined.
KPNAsare important for transport ofNLS-containingcargo.Our
proposed model also predicts that the nucleocytoplasmic traf-
ficking of cNLS-containing cargo will be largely unaffected by
the binding of eVP24. The overlap in the binding also suggests
that PY-STAT1 binding is unlikely to impact normal transport. In
contrast to cNLS cargo, the interaction between eVP24 and
NPI-1 subfamily KPNAs will specifically inhibit PY-STAT1 nuclear
transport and limit the effect of IFNs on EBOV-infected cells. In
addition to providing a mechanism for direct inhibition of cell-
intrinsic immunity, ourmodel allowsus to rationalizehowEBOV-in-
fected cells may continue to function normally during initial stages
of infection, as the nucleocytoplasmic traffickingof cNLS-contain-
ing cargo remain unaffected while JAK/STAT signaling is shut off.
Similar to eVP24, influenza A virus NP and PB2 proteins are
also known to interact with KPNA via ncNLSs; however, the func-
tional consequences of these viral binders of KPNA are distinct
from eVP24. For example, influenza virus NP and PB2 interact
with KPNAs to facilitate viral replication functions, whereas
eVP24 inhibits innate immunity. Moreover, the influenza virus
proteins display distinct specific binding regions and exhibit
different KPNA specificities (Melen et al., 2003; Tarendeau
et al., 2007) (Figure S7). Findings from this study, coupled with
these previous observations, indicate that different viruses may
exploit critical regions on KPNA transporters to enhance viral
replication. By targeting the binding site on KPNAs that is critical
for PY-STAT1 recognition and nuclear transport, EBOV disables
cell-intrinsic antiviral signaling in order to facilitate virus replica-
tion without impacting normal cellular cargo transport. Addi-
tionally, structural insights from our study also provide the
framework for targeting the eVP24/KPNA interface pharmaco-
logically to resensitize Ebola virus to IFNs.EXPERIMENTAL PROCEDURES
Constructs
eVP24 (NCBI accession number AGB56798.1) and KPNA5 (NCBI accession
number NP_002260.2) cDNAs were used as templates to subclone eVP24g
N-terminal importin b binding (IBB) domain followed by 10 ARM repeats, each
4 and STAT1 bind overlapping sites in ARMS 8–10 (highlighted in red, blue, and
lack line, and the additional regions potentially important for PY-STAT1 binding
g the current study.
lls cotransfected with either Flag-KPNA1 or Flag-KPNA5 and Myc-DBC1 and
med on precipitated (IP) material and onwhole-cell lysates (WCLs) for HA, Myc,
or nuclear localization signals (NLSs) span the inner surface of ARMs 2–4 and
of eVP24 is independent of the cNLS sites. Therefore, KPNA loaded with PY-
via a portion of the region used by PY-STAT1 via ARMs 8–10, inhibits PY-STAT1
t & Microbe 16, 187–200, August 13, 2014 ª2014 Elsevier Inc. 197
Cell Host & Microbe
VP24-Karyopherin a Complex Inhibits STAT Signalingconstructs into a modified maltose binding protein (MBP) fusion containing
pET15b vector (Novagen). Mutations were generated using the overlap PCR
method and verified by sequencing.
Protein Expression and Purification
eVP24 and KPNA5 constructs were ectopically expressed in BL21(DE3) E. coli
cells (Novagen) in Luria Broth media. Protein expression was induced at an
OD600 (optical density at 600 nm) of 0.6 with 0.5 mM IPTG and grown for
12–15 hr at 18C.
eVP24 and KPNA5 Constructs
Cells were harvested, resuspended in lysis buffer (buffer L) containing 25 mM
sodium phosphate (pH 7.5), 250mMNaCl, 20mM imidazole, and 5mM2-mer-
captoethanol (BME), lysed using an EmulsiFlex-C5 homogenizer (Avestin),
and clarified by centrifugation at 30,000 3 g at 4C for 30 min. Proteins
were purified using a series of affinity and ion-exchange chromatographic
columns. Following TEV protease digestion to remove theMBP tag, the result-
ing sample was further purified using ion-exchange chromatography to isolate
the protein of interest from the MBP fusion prior to application on a size exclu-
sion column.
eVP24/KPNA5C Complex
Purified eVP24 and KPNA5C were mixed with a 1:1.5 ratio followed by size
exclusion chromatography on a Superdex 75 column (GE Healthcare). The
complex was verified by SDS-PAGE and concentrated to 8 mg/ml. Crystals
were grown by streak seeding into 3.5 M ammonium chloride and 0.1 M Bis-
Tris propane (pH 7.0) at 20C by vapor diffusion.
STAT1 Constructs
All STAT1 constructs were cloned into pET23b with a C-terminal 6xHis-tag or
pET15b and ectopically expressed in BL21(DE3) E. coli cells (Novagen) in LB
media. Protein expression was induced at an OD600 of 0.6 with 0.5 mM IPTG
and grown for 12–15 hr at 18C and purified using methods similar to those
for eVP24 purification.
EGFR Intracellular Domain
Sf9 insect cells growing in Sf900 III media (Gibco) and 1:100 antibiotic antimy-
cotic (Gibco) were infected with baculovirus (1:100) containing EGFR
construct (kind gift fromDr. Bose). At 72 hr postinfection, cells were harvested,
resuspended in buffer L, lysed with a Dounce homogenizer (20 passes), and
clarified by centrifugation at 50,0003 g for 40 min at 10C. EGFR was purified
using a nickel affinity column (GE Healthcare).
PY-STAT1
Kinase reactions were carried out following modified conditions previously
described by Vinkemeier et al. (1996). Briefly, STAT1 at 1 mg/ml in 20 mM
Tris (pH 7.0), 150 mM NaCl, 400 mM ATP, 10 mM MnCl2, 10 mM 2-beta-
mercaptoethanol, and 0.04 mg/ml EGFR was incubated at 30C with no
agitation for 2–4 hr, and the reactions were quenched with 10 mM EDTA
(final) or by direct loading onto a heparin column. PY-STAT1 was further puri-
fied by heparin affinity and size exclusion chromatography (GE Healthcare)
prior to use.
Data Collection and Structure Determination
Crystals were screened at Advanced Photon Source Beamline 19ID and at the
Advanced Light Source Beamline 4.2.2. Diffraction images were collected at
a crystal-to-detector distance of 300 mm, and the data were processed by
HKL3000 (Otwinowski and Minor, 1997). PDB ID 4M0Q was used as a search
model, and the KPNA5C residues were built by three cycles of Bucanneer
(CCP4i) (Winn et al., 2011), manual model building in COOT (Emsley and
Cowtan, 2004), and refinement with REFMAC5 (Collaborative Computational
Project, Number 4, 1994) or PHENIX1.8.4 (Adams et al., 2010). The structure
quality was assessed with MolProbity (Davis et al., 2007).
Coprecipitation Assays
At 24 hr posttransfection with plasmids as indicated in the figure legends, hu-
man embryonic kidney 293T (HEK293T) cells were lysed in NP-40 lysis buffer
(50 mM Tris [pH 7.5], 280 mM NaCl, 0.5% Nonidet P-40, 0.2 mM EDTA, 2 mM
EGTA, 10% glycerol, protease inhibitor [cOmplete; Roche]) and phosphatase
inhibitor (PhosSTOP; Roche). For PY-STAT1 coIPs, HEK293T cells were first
treated with 1000 U/ml human IFNb (PBL) in Dulbecco’s modified Eagle’s
medium (DMEM), 0.3% BSA for 30 min before lysis. Anti-FLAG M2 magnetic
beads or anti-HA beads (Sigma-Aldrich) were incubated with lysates for 1 hr198 Cell Host & Microbe 16, 187–200, August 13, 2014 ª2014 Elseviat 4C, washed five times in NP-40 lysis buffer, and eluted using either 3X
FLAG peptide (Sigma-Aldrich) or by boiling in sample loading buffer.
Isothermal Titration Calorimetry
Binding assays were performed on a VP-isothermal titration calorimeter (VP-
ITC) (Microcal). Protein samples were dialyzed against buffer (10 mM HEPES
[pH 7.0], 150 mM NaCl, and 2 mM TCEP) for 12 hr at 25C. Titrations were
set up with 50–100 mM protein in the syringe and 4–10 mM protein in the cell.
For competition studies such as those in Figure S6, the complex of 1:1 was
used. A reference power of 4 mcal/s and the resulting ITC data were processed
and fit to a one-site binding model to determine n (number of binding sites) and
KD (dissociation constant) using ORIGIN 7.0 software. All experiments were
performed at least in duplicate.
In Vitro Pull-Down Assays Using Recombinantly Expressed Proteins
Amylose resin was pre-equilibrated with buffer (20 mM Tris [pH 7.5], 150 mM
NaCl, 5 mM BME) prior to the addition of lysate containing recombinantly ex-
pressed MBP-tagged proteins at 4C. Resin was incubated for 10 min, fol-
lowed by washes and subsequent resuspension. Purified KPNA5C or VP24
proteins were applied to the resin and allowed to incubate for 20 min, prior
to washes and final resuspension in buffer. Samples were taken at each
step and visualized by Coomassie blue staining of SDS-PAGE.
Reporter Gene Assay
HEK293T cells were transfected with an ISG54 firefly luciferase reporter
plasmid, a constitutively active Renilla luciferase reporter plasmid (pRL-tk;
Promega), and the indicated protein expression plasmids. At 24 hr posttrans-
fection, the cells were treated with 1,000 U/ml human IFNb (PBL) in DMEM,
10% fetal bovine serum. At 24 hr posttreatment, a dual luciferase reporter
assay (Promega) was performed, and firefly luciferase values were normalized
to Renilla luciferase values. Statistical significance was assessed by a one-
way ANOVA using Student’s t test for comparisons as indicated.
Antibodies
Monoclonal mouse anti-FLAG M2 antibody, polyclonal rabbit anti-Flag anti-
body, monoclonal mouse anti-HA antibody, and a polyclonal rabbit anti-HA
antibody were purchased from Sigma-Aldrich. Anti-STAT1 and anti-STAT1
(pY701) were purchased from BD Transduction Laboratories.
Computational Analysis
Atomistic Metropolis Monte Carlo simulations based on the ABSINTH implicit
solvation model (Vitalis and Pappu, 2009) were used to quantify the intrinsic
and context-dependent a-helical propensities of ARM10 helices H1, H2, and
H3. This quantity is calculated using hydrogen-bonding criteria as imple-
mented in the DSSP algorithm (Kabsch and Sander, 1983) and an assessment
of backbone f and c angles. For example, A10H1 in A10H1H2 refers to the hel-
icity of segment H1 of the ARM10 repeat quantified in a simulation that in-
cludes only segments H1 and H2, respectively, whereas A10H1 in A10H1H2H3
refers to the helicity of segment H1 of the ARM10 repeat quantified in a
simulation that includes segments H1, H2, and H3 of ARM10.
STAT1 Nuclear Translocation Assays
The assay was performed as described previously (Reid et al., 2006). Briefly,
Vero cells were seeded onto 12 mm diameter glass coverslips and trans-
fected with empty vector (pCAGGS), VP24 HA (pCAGGS), or VP24 HA
mutants (pCAGGS) using Lipofectamine 2000 (Life Technologies). At 24 hr
posttransfection, cells were serum starved for 4 hr and then either mock
treated or treated with 1,000 U/ml of human IFNb for 30 min at 37C. Cells
were rinsed twice with PBS containing calcium chloride and magnesium
chloride (PBS-CM), fixed with 4% parformaldehyde for 30 min, and blocked
for 45 min at room temperature (RT) with 4% normal goat serum in PBS con-
taining 0.5% BSA and 0.15% glycine (PBG). Subsequently, coverslips were
incubated with rabbit anti-STAT1 (5 mg/ml; Santa Cruz) and mouse anti-
HA (1:200) for 1 hr at RT. Coverslips were rinsed and incubated with Alexa
488-conjugated goat antibody raised against rabbit immunoglobulin G
(IgG), Alexa 555-conjugated antibody raised against mouse IgG, and
Hoechst 33342 (Invitrogen). Images were acquired using an AxioPlan2
fluorescent microscope.er Inc.
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Surface area and surface complementarity were calculated using AREAIMOL
andSc, respectively, as implemented in theCCP4 program suite (Collaborative
Computational Project, Number 4, 1994). Structure figures were prepared
usingPyMOL (DeLano, 2002). Protein-protein interactionswere analyzed using
LigPlot+ (Laskowski and Swindells, 2011). Topology diagrams were generated
by PDBSum (Laskowski, 2007).ACCESSION NUMBERS
Coordinates and structure factors have been deposited in the Protein Data
Bank under PDB ID 4U2X.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.chom.2014.07.008.
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